| Budget Amount *help |
¥29,900,000 (Direct Cost: ¥23,000,000、Indirect Cost: ¥6,900,000)
Fiscal Year 2010: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2009: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
Fiscal Year 2008: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
|
|---|
| Research Abstract |
Primary effusion lymphoma (PEL) is classified as non-Hodgkin's B-cell lymphoma associated with immunocompromised patients such as AIDS patients. PEL cells are universally infected with Kaposi's sarcoma-associated herpesvirus (KSHV). Previously, we had developed anti-tumor compounds, CNDAG and its derivatives, which induce apoptosis in PEL cells. To establish the effective treatment for PEL and KSHV infection, we have demonstrated the mechanisms of action of CNDAG and novel functions, namely anti-herpesviral activities. We furthermore identified sangivamycin, fullerene analogues and sodium valproate as new anti-PEL compounds.
|
